OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Cancer is 100. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis	1509
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	1029
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	956
Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers	928
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	699
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	646
circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis	601
ERK mediates interferon gamma-induced melanoma cell death	598
LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer	567
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	549
Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma	542
CRISPR based therapeutics: a new paradigm in cancer precision medicine	511
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	493
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	481
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	415
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	387
TGF-β signaling promotes cervical cancer metastasis via CDR1as	338
LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling	316
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer	298
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	297
Immunotherapies in rare cancers	293
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway	280
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis	278
Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment	270
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer	265

The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers	248
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3	233
Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC	230
Bidirectional role of neutrophils in tumor development	227
Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities	225
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state	225
Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity	218
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer	215
KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis	212
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	207
Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis	205
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	201
Correction to: The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs	187
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy	185
Biofilm formation by the host microbiota: a protective shield against immunity and its implication in cancer	183
Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells	176
Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation	176
Emerging roles of tRNA-derived fragments in cancer	172
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes	168
Insights into N6-methyladenosine and programmed cell death in cancer	166
PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN	166
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside	163
Effects of RNA methylation on Tumor angiogenesis and cancer progression	160
Nanotechnology-leveraged CRISPR/Cas systems: icebreaking in trace cancer-related nucleic acids biosensing	154
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer	154
NK cells are never alone: crosstalk and communication in tumour microenvironments	154
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	152
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling	149
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection	149
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer	148
Retraction Note: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis	146
Correction: CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	146
Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis	145
Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma	142
lncRNAs: the unexpected link between protein synthesis and cancer adaptation	141
Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment	140
Correction: Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	139
Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells	135
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition	134
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer	134
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer	132
A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression	129
Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation	127
m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma	125
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy	125
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies	124
Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression	123
Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma	122
Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment	121
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance	120

The application of organoids in treatment decision-making for digestive system cancers: progress and challenges	120
An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks	120
CircAKT3 promotes prostate cancer proliferation and metastasis by enhancing the binding of RPS27A and RPL11	119
Crosstalk between autophagy and microbiota in cancer progression	118
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing	117
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer	116
Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy	115
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?	114
Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin	112
Molecular mechanisms of tumor resistance to radiotherapy	112
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring	112
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors	112
Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer	108
Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma	108
Cancer neuroscience in head and neck: interactions, modulation, and therapeutic strategies	108
Correction to: Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma	108
Correction: Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy	107
Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway	106
Profiling of DNA damage and repair pathways in small cell lung cancer reveals a suppressive role in the immune landscape	105
A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions	104
N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1	104
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response	103
Targeting metastasis in paediatric bone sarcomas	102
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond	101
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients	100
A positive feedback circuit driven by m6A-modified circular RNA facilitates colorectal cancer liver metastasis	100